Verrica Pharmaceuticals Inc. (VRCA) stock

VRCANasdaqPharmaceutical PreparationsFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 13, 2026Score 4/30

$3.56−0.16 (-4.30%)

Close on Nov 13, 2026Market cap $61.16MP/E –Yield –

Verrica Pharmaceuticals gross margin

Gross margin is gross profit as a percentage of revenue.

Verrica Pharmaceuticals's gross margin for the twelve months ending Mar 31, 2025 was 63.8%. For fiscal 2024 it was 65.6%, against 90.2% the year before.

Annual gross margin

Period	Period end	Value	Change (pts)
FY2024	Dec 31, 2024	65.6%	−24.6
FY2023	Dec 31, 2023	90.2%	–

Quarterly gross margin

Change is against the same quarter a year earlier.

Period	Period end	Value	Change (pts)
Q1 FY2025	Mar 31, 2025	79.6%	−10.3
Q4 FY2024	Dec 31, 2024	-132.6%	−222.3
Q2 FY2024	Jun 30, 2024	86.5%	–
Q1 FY2024	Mar 31, 2024	81.7%	–
Q4 FY2023	Dec 31, 2023	89.9%	–
Q3 FY2023	Sep 30, 2023	89.7%	–

Where these numbers come from

Parsed from the XBRL in Verrica Pharmaceuticals's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-10 reverse split on Jul 25, 2025
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing